Quick Answer
Onconetix, Inc. reported Cash and Equivalents of $25.75 million for fiscal year 2022.
Onconetix, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2022 | $25.75M | +1235.4% |
| 2021 | $1.93M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2022 | $29.14M | — | +31.0% |
| June 30, 2022 | $22.24M | — | +19.5% |
| March 31, 2022 | $18.61M | — | +865.0% |
| December 31, 2021 | $1.93M | — | — |
- Onconetix, Inc. showed an increase of +1235.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2022 period, Onconetix, Inc.’s cash and equivalents has grown by 1235.4% (from $1.93 million to $25.75 million).
- The most recent figure is from Onconetix, Inc.’s fiscal year 2022 report (Form 10-K), filed with the SEC on March 9, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: